)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Nykode Therapeutics
Nykode Therapeutics (NYKD) investor relations material
Nykode Therapeutics H.C. Wainwright 28th Annual Global Investment Conference presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H.C. Wainwright 28th Annual Global Investment Conference presentation summary16 Sep, 2026
Investment highlights
Abi-suva, an off-the-shelf cancer vaccine, shows strong efficacy in HPV16+ head & neck cancer with a 38.5% ORR versus 19% for standard of care and a favorable safety profile.
Ongoing randomized Phase 2 Abili-T trial in 1L r/m HPV16+ head & neck cancer, with interim analysis expected in 2027.
Individualized neoantigen therapy (VB10.NEO) validated with positive peer Phase 3 data, strong immune responses in 100% of patients, and correlation with survival.
Proprietary neoantigen selection algorithm and simpler pDNA manufacturing support competitive costs and turnaround times.
Well-capitalized with $44.8M cash at Q2 2026 and $30.7M raised in August 2026, plus potential $35M upside from a pending tax case.
Pipeline and clinical progress
Abi-suva demonstrates consistent ORR improvement across head & neck and cervical cancer trials, with 39% ORR in 1L head & neck cancer.
VB10.NEO shows strong immunogenicity across 13 tumor types and 67 patients, with immune responses correlating with survival.
Tolerance platform for autoimmune diseases is in preclinical stage, with development planned for 1H 2027.
Abili-T Phase 2 trial protocol approved in 8 European countries, first patient dosed in May 2026, and enrollment expanding.
Clinical data and immune response
Abi-suva combined with checkpoint inhibitors doubles ORR compared to monotherapy in head & neck and cervical cancer.
HPV16-specific T-cell responses are strongly associated with lesion size reduction and clinical outcomes.
VB10.NEO induces long-lasting T-cell memory and de novo immune responses, with antigen-specific immunogenicity correlating with overall survival.
Manufacturing process for VB10.NEO is optimized for turnaround time under 6 weeks, competitive with peers.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Nykode Therapeutics
- Lead oncology and autoimmune assets show strong efficacy, supported by AI and a solid cash runway.NYKD
Company presentation - Lead assets advance in trials, strong cash reserves, and peer validation support growth.NYKDQ2 2026
- AI-driven APC-targeting vaccines show strong, durable immune responses and clinical promise.NYKDInvestor presentation
- APC-targeted vaccines show strong preclinical efficacy and major partnerships exceeding $1.6B.NYKDPEGS EUROPE 2024 presentation
- Individualized cancer vaccine platform shows robust, durable immune responses and strong safety.NYKDPersonalized cancer vaccine summit presentation
- AI-powered APC-targeted vaccines show durable efficacy in cancer and autoimmune models.NYKDASIT 2025 presentation
- APC-targeted immunotherapies deliver durable, antigen-specific efficacy and rapid clinical progress.NYKD9th ASIT 2026 presentation
- Abi-suva plus pembrolizumab achieved strong immune responses and 38.5% ORR in HPV16+ OPC.NYKDICHNO 2026 presentation
- Individualized neoantigen vaccines show robust, durable immunity and streamlined production.NYKDVB10.NEO presentation
Next Nykode Therapeutics earnings date
Q3 202625 Nov, 2026
Nykode Therapeutics
Next Nykode Therapeutics earnings date
Q3 202625 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company based in Oslo, Norway. The company focuses on the discovery and development of novel vaccines and immunotherapies, primarily targeting cancer and infectious diseases. Nykode leverages its proprietary modular vaccine technology, which directs antigens to antigen-presenting cells, aiming to induce strong and long-lasting immune responses. Its leading product candidates include VB10.16, a therapeutic vaccine in development for human papillomavirus (HPV)-related cancers, and VB10.NEO, a cancer neoantigen vaccine, which is in clinical trials for several types of advanced tumors. The company is headquartered in Oslo, Norway, and its shares are listed on the Oslo Stock Exchange.